Breast cancer (BC) has been identified as an increasing risk among the female cancer patients of West Bengal. Mutations in breast cancer susceptibility genes, BRCA1 and BRCA2 account for more than 80% of hereditary breast and ovarian cancers. To explore the contribution of BRCA1mutations in the development of hereditary BC among these women, we carried out mutation analysis of the BRCA1genein 231BCpatients from eastern India.
130 proband with positive family history and 101 without family history were selected from a tertiary cancer hospital, Kolkatafor the detection of BRCA1 mutations. To predict the functional effect of novel mutations in BRCA1 gene, in-silico analysis and m-RNA folding were performed. Surveillance and preventive measures were proposed to the high-risk individuals.
In total, 18 (7.79%) genetic alterations were identified. Interestingly, 5382insC, a BRCA1 mutation which occurs at a very high frequency in Ashkenazi Jews, was found at a frequency of 3.03% (7/231).Among our patients, two novel missense variants (c.5237AÃ C; c.5210 GÃ A)and one novel frame shift mutation (c.4495GC > C) were identified, as evidenced from the Human Genome Variation Society (HGVS) or Breast Cancer Information Core (BIC). Other mutations were UTR-17insg (n = 3); UTR -17ins g and UTR-13gÃ c (n = 2), UTR-13gÃ c (n = 1), c.75CÃ A (n = 1) and c.4675 + 1GÃ A (n = 1). The in-silicoanalysis revealed that both the novel mutations probably alters the structure and reduces the protein stability of BRCA1.
Thus, our study emphasizes the importance of mutation screening in familial BC, and the potential implications of these findings in genetic counseling and preventive therapy.
Clinical trial identification
All authors have declared no conflicts of interest.